Michaela Lackner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1951614/publications.pdf

Version: 2024-02-01

101 papers

5,557 citations

34 h-index 71 g-index

106 all docs

106 docs citations

106 times ranked 5048 citing authors

#	Article	IF	CITATIONS
1	An overview of using fungal DNA for the diagnosis of invasive mycoses. Expert Review of Molecular Diagnostics, 2022, 22, 169-184.	1.5	18
2	N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro. Emerging Microbes and Infections, 2022, , 1-49.	3.0	7
3	Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. Medical Mycology, 2021, 59, 126-138.	0.3	27
4	Impact of biofilm formation and azoles' susceptibility in Scedosporium/Lomentospora species using an in vitro model that mimics the cystic fibrosis patients' airway environment. Journal of Cystic Fibrosis, 2021, 20, 303-309.	0.3	9
5	<i>N</i> â€ehlorotaurine, a potent weapon against multiresistant bacteria. Journal of Applied Microbiology, 2021, 131, 1742-1748.	1.4	8
6	The Environmental Spread of Aspergillus terreus in Tyrol, Austria. Microorganisms, 2021, 9, 539.	1.6	7
7	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The. 2021. 21. e246-e257.	4.6	167
8	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. Antimicrobial Agents and Chemotherapy, 2021, 65, e0109321.	1.4	12
9	EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence. Journal of Antimicrobial Chemotherapy, 2021, 77, 253-258.	1.3	13
10	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	1.5	5
11	Sterol $14\hat{1}\pm$ -Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. Journal of Fungi (Basel, Switzerland), 2021, 7, 1.	1.5	67
12	Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. Blood Cancer Journal, 2020, 10, 75.	2.8	2
13	Comparative immunopathogenesis in a murine model of inhalative infection with the mucormycetes Lichtheimia corymbifera and Rhizopus arrhizus. PLoS ONE, 2020, 15, e0234063.	1.1	6
14	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeⓇ—Global Registry for Emerging Fungal Infections. Journal of Infection, 2020, 81, 802-815.	1.7	20
15	Microbicidal activity of N-chlorotaurine can be enhanced in the presence of lung epithelial cells. Journal of Cystic Fibrosis, 2020, 19, 1011-1017.	0.3	3
16	Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?. Clinical Microbiology and Infection, 2020, 26, 1024-1033.	2.8	23
17	Polymorphisms within the <i>ARNT2</i> and <i>CX3CR1</i> Genes Are Associated with the Risk of Developing Invasive Aspergillosis. Infection and Immunity, 2020, 88, .	1.0	8
18	Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing Saccharomycotina yeasts. Medical Mycology, 2020, 58, 987-995.	0.3	14

#	Article	IF	Citations
19	<i>Galleria mellonella</i> as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. Medical Mycology, 2019, 57, 351-362.	0.3	54
20	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2019, 74, 532-533.	1.3	3
21	Cryptic species of <i>Aspergillus</i> section <i>Terrei</i> display essential physiological features to cause infection and are similar in their virulence potential in <i>Galleria mellonella</i> Virulence, 2019, 10, 542-554.	1.8	14
22	Evaluation of a Novel Mitochondrial Pan-Mucorales Marker for the Detection, Identification, Quantification, and Growth Stage Determination of Mucormycetes. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT / G	Ov ert ock 1	0 T 950 617
23	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
24	A European ECMMâ€ESCMID survey on goals and practices for mycobiota characterisation using nextâ€generation sequencing. Mycoses, 2019, 62, 1096-1099.	1.8	8
25	The Emergence of Rare Clinical Aspergillus Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles. Frontiers in Microbiology, 2019, 10, 1677.	1.5	22
26	Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance. Journal of Fungi (Basel, Switzerland), 2019, 5, 83.	1.5	10
27	"Enhanced acquisition of antibiotic-resistant intestinal E. coli during the first year of life assessed in a prospective cohort studyâ€. Antimicrobial Resistance and Infection Control, 2019, 8, 79.	1.5	12
28	Antifungal susceptibility profiles of rare ascomycetous yeasts. Journal of Antimicrobial Chemotherapy, 2019, 74, 2649-2656.	1.3	22
29	Recent trends in molecular diagnostics of yeast infections: from PCR to NGS. FEMS Microbiology Reviews, 2019, 43, 517-547.	3.9	77
30	The changing spectrum of Saccharomycotina yeasts causing candidemia: phylogeny mirrors antifungal susceptibility patterns for azole drugs and amphothericin B. FEMS Yeast Research, 2019, 19, .	1.1	30
31	<i>Candida</i> in the Respiratory Tract Potentially Triggers Galactomannan Positivity in Nonhematological Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17
32	Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	39
33	High percentage of microbial colonization of osteosynthesis material in clinically unremarkable patients. MicrobiologyOpen, 2019, 8, e00658.	1.2	16
34	Prognostic factors in 264 adults with invasive (i) Scedosporium (i) spp. and (i) Lomentospora prolificans (i) infection reported in the literature and FungiScope (sup) \hat{A}^{\otimes} (sup). Critical Reviews in Microbiology, 2019, 45, 1-21.	2.7	106
35	Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing. PLoS ONE, 2019, 14, e0210397.	1.1	53
36	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	59

#	Article	IF	Citations
37	Novel multiplex real-time quantitative PCR detecting system approach for direct detection of <i>Candida auris</i> and its relatives in spiked serum samples. Future Microbiology, 2019, 14, 33-45.	1.0	38
38	YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagnostic Microbiology and Infectious Disease, 2019, 93, 112-119.	0.8	42
39	Direct detection of Exophiala and Scedosporium species in sputa of patients with cystic fibrosis. Medical Mycology, 2018, 56, 695-702.	0.3	16
40	Scedosporium and Lomentospora: an updated overview of underrated opportunists. Medical Mycology, 2018, 56, S102-S125.	0.3	186
41	N-Chlorotaurine, a Promising Future Candidate for Topical Therapy of Fungal Infections. Mycopathologia, 2018, 183, 161-170.	1.3	24
42	403. Prognostic Factors in 260 Adults With Invasive Scedosporiosis From Literature and FungiScopeâ,,¢. Open Forum Infectious Diseases, 2018, 5, S155-S155.	0.4	0
43	Azole-resistant and -susceptible Aspergillus fumigatus isolates show comparable fitness and azole treatment outcome in immunocompetent mice. Medical Mycology, 2018, 56, 703-710.	0.3	8
44	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	1.5	66
45	A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. Infection, 2018, 46, 701-704.	2.3	11
46	Proof of Concept for MBT ASTRA, a Rapid Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS)-Based Method To Detect Caspofungin Resistance in Candida albicans and Candida glabrata. Journal of Clinical Microbiology, 2018, 56, .	1.8	52
47	Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. Journal of Antimicrobial Chemotherapy, 2018, 73, 3068-3073.	1.3	32
48	Voriconazole MICs are predictive for the outcome of experimental disseminated scedosporiosis. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw532.	1.3	14
49	Pan-azole-resistantCandida tropicaliscarrying homozygouserg11mutations at position K143R: a new emerging superbug?. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw558.	1.3	35
50	Bactericidal and Fungicidal Activity of $\langle i \rangle N \langle i \rangle$ -Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	27
51	A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. Clinical Microbiology and Infection, 2017, 23, 776.e1-776.e5.	2.8	42
52	Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. Infection, 2017, 45, 867-875.	2.3	19
53	Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	7
54	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14î±-demethylase. Scientific Reports, 2017, 7, 15898.	1.6	59

#	Article	IF	Citations
55	Retrospective case study on the suitability of mid-infrared microscopic imaging for the diagnosis of mucormycosis in human tissue sections. Analytical Methods, 2017, 9, 4135-4142.	1.3	4
56	Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	47
57	Commercial Molecular Tests for Fungal Diagnosis from a Practical Point of View. Methods in Molecular Biology, 2017, 1508, 85-105.	0.4	10
58	Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis. Frontiers in Microbiology, 2016, 7, 1243.	1.5	13
59	Geographically predominant genotypes of Aspergillus terreus species complex in Austria: s microsatellite typing study. Clinical Microbiology and Infection, 2016, 22, 270-276.	2.8	23
60	Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. Infection and Immunity, 2016, 84, 643-657.	1.0	35
61	Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis. Clinical Microbiology and Infection, 2016, 22, 80-86.	2.8	60
62	The â€~species complex' issue in clinically relevant fungi: A case study in Scedosporium apiospermum. Fungal Biology, 2016, 120, 137-146.	1.1	54
63	DNA barcoding of fungi causing infections in humans and animals. Fungal Biology, 2016, 120, 125-136.	1.1	67
64	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. Journal of Medical Microbiology, 2016, 65, 1414-1421.	0.7	62
65	Diagnostic accuracy of the <i>Aspergillus</i> \$especific bronchoalveolar lavage lateralâ€flow assay in haematological malignancy patients. Mycoses, 2015, 58, 461-469.	1.8	51
66	<i>N</i> -Chlorotaurine Exhibits Fungicidal Activity against Therapy-Refractory Scedosporium Species and Lomentospora prolificans. Antimicrobial Agents and Chemotherapy, 2015, 59, 6454-6462.	1.4	16
67	Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: realâ€life data from a retrospective singleâ€centre observational study. European Journal of Haematology, 2015, 94, 258-264.	1.1	35
68	Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions. Antimicrobial Agents and Chemotherapy, 2015, 59, 1344-1346.	1.4	15
69	Multidrug- and Cross-Resistant Candida: the Looming Threat. Current Fungal Infection Reports, 2015, 9, 23-36.	0.9	3
70	Evaluation of a Modified EUCAST Fragmented-Mycelium Inoculum Method for <i>In Vitro</i> Susceptibility Testing of Dermatophytes and the Activity of Novel Antifungal Agents. Antimicrobial Agents and Chemotherapy, 2015, 59, 3675-3682.	1.4	12
71	Effect of Reduced Oxygen on the Antifungal Susceptibility of Clinically Relevant Aspergilli. Antimicrobial Agents and Chemotherapy, 2015, 59, 1806-1810.	1.4	12
72	Etest Cannot Be Recommended for <i>In Vitro</i> Susceptibility Testing of Mucorales. Antimicrobial Agents and Chemotherapy, 2015, 59, 3663-3665.	1.4	29

#	Article	IF	CITATIONS
73	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Critical Care, 2015, 19, 178.	2.5	65
74	Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. British Journal of Cancer, 2015, 113, 970-978.	2.9	21
75	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	1.8	65
76	1462Bronchoalveolar Lavage Lateral-Flow Device Test for Diagnosing Invasive Pulmonary Aspergillosis in ICU patients: a multicenter study. Open Forum Infectious Diseases, 2014, 1, S385-S386.	0.4	1
77	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients: A Semi-Prospective Multicenter Study Transplantation, 2014, 98, 775.	0.5	0
78	Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiology, 2014, 9, 683-695.	1.0	105
79	Phylogenetic Relationships Matter: Antifungal Susceptibility among Clinically Relevant Yeasts. Antimicrobial Agents and Chemotherapy, 2014, 58, 1575-1585.	1.4	26
80	Positions and Numbers of <i>FKS</i> Mutations in Candida albicans Selectively Influence <i>In Vitro</i> and <i>In Vivo</i> Susceptibilities to Echinocandin Treatment. Antimicrobial Agents and Chemotherapy, 2014, 58, 3626-3635.	1.4	59
81	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients. Transplantation, 2014, 98, 898-902.	0.5	54
82	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	2.8	383
83	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	2.8	262
84	ESCMID†and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	2.8	547
85	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	4.7	152
86	Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium. Antimicrobial Agents and Chemotherapy, 2014, 58, 5877-5885.	1.4	61
87	Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii. Journal of Antimicrobial Chemotherapy, 2014, 69, 3027-3032.	1.3	16
88	<i>In Vitro</i> Antifungal Susceptibility of Candida glabrata to Caspofungin and the Presence of <i>FKS</i> Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3646-3649.	1.4	10
89	Feasibility of mitochondrial single nucleotide polymorphisms to detect and identify Aspergillus fumigatus in clinical samples. Diagnostic Microbiology and Infectious Disease, 2014, 80, 53-58.	0.8	8
90	Taxonomy of medically important fungi in the molecular era. Lancet Infectious Diseases, The, 2013, 13, 385-386.	4.6	31

#	Article	IF	CITATIONS
91	Pathogenesis of Scedosporium. Current Fungal Infection Reports, 2013, 7, 326-333.	0.9	19
92	<i>In vitro</i> activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses, 2013, 56, 297-303.	1.8	29
93	SNaPAfu: A Novel Single Nucleotide Polymorphism Multiplex Assay for Aspergillus fumigatus Direct Detection, Identification and Genotyping in Clinical Specimens. PLoS ONE, 2013, 8, e75968.	1.1	13
94	Up-date on Diagnostic Strategies of Invasive Aspergillosis. Current Pharmaceutical Design, 2013, 19, 3595-3614.	0.9	50
95	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	1.4	244
96	Rapid Identification of Pseudallescheria and Scedosporium Strains by Using Rolling Circle Amplification. Applied and Environmental Microbiology, 2012, 78, 126-133.	1.4	44
97	Young ISHAM – Uniting Young Scientists from all over the World. Current Fungal Infection Reports, 2012, 6, 346-348.	0.9	O
98	PHP124 Personalized Decision Making in Cancer Medicine? Systematic Overview of HTA Procedures and Specific Approaches in Ten Countries Across Four Continents. Value in Health, 2011, 14, A355-A356.	0.1	0
99	Severe prosthetic joint infection in an immunocompetent male patient due to a therapy refractory <i>Pseudallescheria apiosperma</i> . Mycoses, 2011, 54, 22-27.	1.8	26
100	Identification of Pseudallescheria and Scedosporium Species by Three Molecular Methods. Journal of Clinical Microbiology, 2011, 49, 960-967.	1.8	51
101	Parascedosporium and its relatives: phylogeny and ecological trends. IMA Fungus, 2011, 2, 39-48.	1.7	28